Welcome to our dedicated page for Baudax Bio news (Ticker: BXRX), a resource for investors and traders seeking the latest updates and insights on Baudax Bio stock.
Baudax Bio, Inc. (NASDAQ: BXRX) is a specialized pharmaceutical company focused on developing and commercializing innovative products designed to meet the needs of hospital and acute care settings. The company's lead product candidate is an intravenous form of meloxicam, a non-opioid analgesic that has completed Phase III clinical trials for the management of moderate to severe pain. Current research includes Phase IIIB clinical trials aiming to assess opioid consumption, pain intensity, and the length of hospital stay in colorectal and orthopedic surgery patients. These trials also evaluate various pharmacoeconomic parameters.
Beyond meloxicam, Baudax Bio is advancing a pipeline of early-stage product candidates including RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) in Phase I clinical trials, and RP2000, an ultra-short-acting NMBA currently in pre-clinical trials. The company is also developing a reversal agent for these NMBAs and DEX-IN, a proprietary intranasal formulation of dexmedetomidine.
Recently, Baudax Bio announced that the U.S. FDA has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is a next-generation Treg therapy designed to address Hemophilia A patients with FVIII inhibitors effectively.
Founded in 2019 and based in Malvern, Pennsylvania, Baudax Bio continues to push forward with its mission to develop meaningful therapeutic solutions for acute care settings, drawing on robust clinical research and innovative therapeutic approaches.
Baudax Bio (NASDAQ:BXRX) has initiated a First-in-Man, Phase 1 clinical trial for BX2000, an ultra-short acting neuromuscular blocking agent. The study will evaluate safety and pharmacokinetics, involving 10 dosing cohorts with 8 patients each. Participants will be closely monitored for 24 hours post-dosing, with follow-up visits at 2 and 4 weeks. CEO Gerri Henwood emphasized the potential of BX2000 to improve intubation processes and recovery times. This marks a significant step in the development of Baudax's neuromuscular blockers.
Baudax Bio (NASDAQ:BXRX) announced that Gerri Henwood, President and CEO, will present at the H.C. Wainwright Annual Global Life Sciences Conference on May 25, 2022, at 1:30 p.m. Eastern Time in Miami, Florida. A webcast of the presentation will be available on the company's investors page and archived for 90 days. Baudax Bio focuses on innovative products for acute care, including its flagship product, ANJESO, the first intravenous COX-2 preferential NSAID for moderate to severe pain, along with a promising pipeline of neuromuscular blocking agents.
Baudax Bio (BXRX) has entered a definitive agreement to sell 1,646,091 shares of common stock at $1.215 each, raising approximately $2.0 million before expenses. Additionally, the company will issue unregistered warrants to purchase the same number of shares at an exercise price of $1.09. The offering is expected to close on or about May 19, 2022. Proceeds will support the commercialization of ANJESO, pipeline development, and general corporate purposes. The shares are being offered under an effective shelf registration statement.
Baudax Bio, Inc. (NASDAQ:BXRX) has postponed its 2022 Annual Meeting of Shareholders due to insufficient participation, failing to reach quorum. The meeting will now take place on May 18, 2022, at 9:00 a.m. Eastern Time, and will continue virtually. Shareholders eligible to vote are those registered by the close of business on March 29, 2022. Votes submitted prior will remain valid for the reconvened meeting. The company focuses on innovative pharmaceutical solutions for acute care settings, including its product ANJESO, the first 24-hour IV COX-2 preferential NSAID.
Baudax Bio, Inc. (NASDAQ:BXRX) reported a 113% increase in ANJESO net product revenue for Q1 2022, totaling $0.4 million. This marks the sixth consecutive quarter of demand growth, with March 2022 recording the highest sales month since launch. The company initiated a Phase IV clinical trial for pediatric use of ANJESO and is advancing its neuromuscular blocking agents. Financially, Baudax secured $10 million through a public offering, reducing its burn rate by 65%.
Baudax Bio, Inc. (NASDAQ:BXRX) will report its first quarter 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss these results and operational updates. The call can be accessed by dialing (866) 220-5595 for local and (615) 622-8062 for international calls. ANJESO, Baudax’s primary product, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets, including neuromuscular blocking agents.
Baudax Bio (NASDAQ:BXRX) announced that CEO Gerri Henwood will present at the Noble Capital Markets’ 18th Annual Investor Conference on April 20, 2022, at 3:30 p.m. ET in Hollywood, Florida. A webcast of this presentation will be available the next day on the company's website along with an archived version for 90 days.
Additionally, Henwood will participate in breakout sessions on April 20 at 12:15 p.m. ET and April 21 at 10:45 a.m. ET, providing further engagement opportunities.
Baudax Bio (NASDAQ:BXRX) reported its Q4 and full-year 2021 financial results, highlighting a 32% increase in demand for ANJESO from Q3 to Q4 and a 45% rise in units sold to ambulatory surgical centers. Despite pandemic-related challenges, net product revenue for ANJESO grew to $0.4 million in Q4 and $1.1 million for the year. The company also announced a $10 million public offering and plans to reduce expenses, including an 80% workforce cut. Following a 1-for-35 reverse stock split, it regained NASDAQ compliance. However, it reported a net loss of $19.8 million for 2021.
Baudax Bio, a pharmaceutical company focused on acute care products, announced that CEO Gerri Henwood will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 2:40 p.m. ET. A live webcast of the presentation will be available on the company's investors page, and a replay will be accessible for 30 days post-event.
Baudax Bio is known for ANJESO, the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain, alongside a pipeline of innovative pharmaceutical products.
Baudax Bio (NASDAQ:BXRX) has initiated a clinical study to evaluate the safety and pharmacokinetics of ANJESO (meloxicam) injection in pediatric patients aged 2 to <17 years following elective surgery. This multicenter trial will enroll approximately 90 patients across three age groups. ANJESO, a non-opioid pain management option, is gaining traction in the adult market and is expected to address a significant need in pediatric surgery, with an estimated 3.9 million elective procedures annually in the U.S.
FAQ
What is the market cap of Baudax Bio (BXRX)?
What is the primary focus of Baudax Bio, Inc.?
What is Baudax Bio's lead product candidate?
What other products are in Baudax Bio's pipeline?
What recent regulatory milestone has Baudax Bio achieved?
Where is Baudax Bio headquartered?
When was Baudax Bio incorporated?
What is the status of meloxicam's clinical trials?
What is TI-168?
Who can I contact for investor relations information?
Are there any other clinical trials Baudax Bio is involved in?
